CriticalTriptan, selective 5HT1B/1D receptor agonist×Selective irreversible MAO-B inhibitor
Updated · Methodology
Mechanism
At recommended doses, selegiline inhibits monoamine oxidase type B (MAO-B) selectively and irreversibly, and above 10 mg a day it may lose this selectivity (selegiline summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.4, 5.1 and 5.2). Eletriptan is a selective agonist of serotonin 5-HT1B and 5-HT1D receptors, and CYP3A4 is the main enzyme that metabolises it (eletriptan SmPC, AEMPS, sections 5.1 and 5.2). The selegiline SmPC contraindicates selegiline with serotonin agonists because of the risk of serious interactions that can lead to serotonin syndrome. Eletriptan is not among the examples, but its own SmPC places it in this class (selegiline SmPC, AEMPS, section 4.5). According to the Spanish eletriptan SmPC, eletriptan is not a substrate of monoamine oxidase, so no interaction with monoamine oxidase inhibitors is expected, and no formal interaction studies have been done (eletriptan SmPC, AEMPS, section 4.5). The US eletriptan label nevertheless warns that serotonin syndrome may occur, particularly with monoamine oxidase inhibitors, which is the risk named in the selegiline SmPC (eletriptan label, US Food and Drug Administration, FDA, section 5.7).
Symptoms
The documents do not describe how this particular combination presents, but the selegiline summary of product characteristics (SmPC) warns that serious interactions with serotonin agonists can lead to serotonin syndrome (Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Signs of serotonin syndrome include mental status changes (agitation, hallucinations, coma), autonomic instability (fast heart rate, labile blood pressure, high temperature), neuromuscular changes (overactive reflexes, poor coordination), nausea, vomiting and diarrhoea. It usually starts within minutes to hours of a new or higher dose of a serotonergic drug (eletriptan label, US Food and Drug Administration, FDA, section 5.7). Eletriptan itself can cause chest pain and tightness, sometimes intense and spreading to the throat. At doses of 60 mg or more, it can cause a slight transient rise in blood pressure, much more marked in older people and in kidney impairment. Rises in blood pressure have also been reported at 20 and 40 mg (eletriptan SmPC, AEMPS, section 4.4). On rare occasions 5-HT1 agonists have caused significant rises in blood pressure, up to hypertensive crisis with acute impairment of organ systems (FDA eletriptan label, section 5.8). Above the recommended 10 mg a day, selegiline may lose its selectivity for monoamine oxidase type B (MAO-B), which raises the risk of hypertension (selegiline SmPC, AEMPS, section 4.4).
Management
The combination is contraindicated: do not prescribe eletriptan to people taking selegiline. The selegiline summary of product characteristics (SmPC) lists serotonin agonists among contraindicated combinations (Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Eletriptan is not among the examples in that sentence, but its own SmPC describes it as a selective agonist of serotonin 5-HT1B and 5-HT1D receptors (eletriptan SmPC, AEMPS, section 5.1), so the class contraindication applies to it as well. The eletriptan documents are softer, but this does not lift the contraindication in the selegiline SmPC. The Spanish eletriptan SmPC expects no interaction with monoamine oxidase inhibitors (eletriptan SmPC, AEMPS, section 4.5). The US Food and Drug Administration (FDA) label does not list monoamine oxidase inhibitors among its contraindications but warns of serotonin syndrome with them (FDA eletriptan label, sections 4 and 5.7). No document gives an interval between stopping selegiline and the first dose of eletriptan, or for the opposite switch. Selegiline inhibits monoamine oxidase type B (MAO-B) irreversibly, and after a single 10 mg dose platelet MAO-B activity returns to normal in about 2 weeks (selegiline SmPC, AEMPS, section 5.2). If the two drugs have nevertheless been taken together and serotonin syndrome is suspected, stop eletriptan (FDA eletriptan label, section 5.7). Monitor blood pressure during eletriptan treatment (FDA eletriptan label, section 5.8). Eletriptan is contraindicated in severe or moderately severe hypertension and in untreated mild hypertension (eletriptan SmPC, AEMPS, section 4.3). If chest pain and tightness suggest cardiac ischaemia, withhold further eletriptan doses and assess the patient (eletriptan SmPC, AEMPS, section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Relpax (eletriptan hydrobromide) tablets – prescribing information (2024)– FDA label, Viatris Specialty, DailyMed setid 2a501dbd-3ea8-47e4-9fcb-07035b8c8c9e, version 4, 01/2024, sections 4, 5.7, 7.1, 7.2 and 7.3
- AEMPS: Ficha técnica: Selegilina, Plurimen 5 mg (nº registro 58113) (2026)– AEMPS, CIMA, nº registro 58113 (Plurimen 5 mg comprimidos), revisión 03/2026, secciones 4.3, 4.4, 4.5 y 5.1
- AEMPS: Ficha técnica: Eletriptán (nº registro 64124), sección 4.3 (2024)– AEMPS, CIMA, nº registro 64124 (Relpax 20 mg, Viatris), revisión 05/2024, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Eletriptán (nº registro 64124), sección 4.5 (2024)– AEMPS, CIMA, nº registro 64124 (Relpax 20 mg, Viatris), revisión 05/2024, secciones 4.4 y 4.5